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Crystallization of a solution with high enantiomeric excess 
can generate a mixture of crystals of the desired enantiomer 
and the racemic compound. Using a mixture of S-/RS-
ibuprofen crystals as a model, we demonstrated that magnetic 
levitation (MagLev) is a useful technique for analysis, 
separation and enantioenrichment of chiral/racemic 
products. 
The enantiomeric purity of pharmaceutical compounds is important 
because enantiomers/racemates of a drug can have different effects 
(i.e. therapeutic or harmful).1 In the late 1950s, the racemic mixture 
of Thalidomide, for example, was widely prescribed to relieve the 
symptoms of morning sickness in pregnant women. Nevertheless, 
the drug was withdrawn in 1962 after a birth defects crisis, where it 
was later discovered that the (R) enantiomer is effective against 
morning sickness while the (S) enantiomer causes birth defects.2 
Apart from therapeutic effects and safety, efficacy of a pure 
enantiomer is another area of interest.3 For example, S-ibuprofen has 
anti-inflammatory activity that is 150 times higher than that of R-
ibuprofen.4 As a result, this subject is not only of interest to 
pharmaceutical companies but also to the Food and Drug 
Administration (FDA) who tends to verifying and marketing most 
chiral drugs as single enantiomers. In fact, in 2006, approximately 
80% of small-molecule drugs approved by the FDA were chiral and 
75% of them were single enantiomers.5 There is need to develop new 
approaches to analyze enantiomeric purity and obtain pure 
enantiomers. Asymmetric synthesis, chiral resolution and isolation 
of enantiomerically pure compounds (e.g., from biological sources) 
are common methods to produce enantiopure compounds.6 In many 
cases, even with efficient purifications, the products are a mixture of 
the desired enantiomer and a small or considerable amount of the 
undesired enantiomer. For example, the active pharmaceutical 
ingredient used in the treatment of Parkinson’s disease (L-3,4-
dihydroxyphenylalanine), is manufactured with an asymmetric 
synthesis step yielding 95%ee.6 After synthesis, L-enantiomer is 
purified by either high-performance liquid chromatography (HPLC) 
or formation of diastereomers followed by crystallization. These two 
methods, though commonly used to obtain single enantiomers, have 
three disadvantages: (i) Separation by HPLC require expensive 
instrumentation and stationary phase.1 (ii) A particular chiral 
stationary phase may only work for a limited number of 
compounds.6,7 (iii) Formation of diastereomers introduces another 
compound into the system, and requires additional crystallization 
and filtration steps.7 
    One of the alternative approaches to solution-based separation of 
enantiomers is to purify the desired enantiomer from a mixture of 
crystals of enantiomerically pure and racemic compound. Given a 
solution with high enantiomeric excess, one crystallization step 
usually generates crystals of the desired enantiomer contaminated 
with crystals of the racemic compound.8,9 Since the racemic 
compound and pure enantiomers have different densities, MagLev 
can be used as a cost-effective, and non-destructive method to 
separate the enantiomerically pure crystals (desired products) from 
the racemic compound crystals (“impurity”).  
 
Figure 1. Diamagnetic particles with different densities suspended in a 
paramagnetic medium can be levitated to different heights when container is 
placed between the magnets of MagLev device. 
    The theory of MagLev is described in details elsewhere.10,11,12 
Briefly, under the influence of an external magnetic field, dia-
magnetic materials of different densities (suspended in a para-
magnetic medium) can be levitated to different heights by the 
balance of magnetic and gravitational forces (Figure 1). Since most 
materials (especially most organic compounds) are diamagnetic, 
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MagLev can find broad applications in density-based analysis and 
separations in the pharmaceutical industry. We have demonstrated 
the use of MagLev to separate mixtures of crystal polymorphs.13 
Here, we describe the use of MagLev for analysis of enantiomeric 
purity and enrichment (Figure 2). We selected a mixture of 
enantiomerically pure and racemic crystals of ibuprofen to 
demonstrate the concept; S-ibuprofen is metabolically “cleaner” 
than racemic ibuprofen.14 We also performed the separation of S-
phebox from RS-phebox (See Supporting Information). Phebox is 
generally used as an efficient auxiliary for asymmetric catalysis and 
its enantiomeric purity is vital since it provides appropriate 
stereochemical and electronic circumstances. To our knowledge, this 
is the first report on analysis of enantiomer purity, and enantio-
enrichment based on density using MagLev. 
 
Figure 2. Schematic illustration of the separation of enantiopure crystals from 
racemic crystals of ibuprofen by density using MagLev. . Using ibuprofen as a 
model ystem, MagLev enables separation and isolation of S-Ibuprofen and RS-
Ibuprofen by their difference in density. This method can be used as a general 
method to analyze enantiomeric purity of a mixture or purify enantiomer product 
for further use. The densities of S-ibuprofen and RS-ibuprofen are reported to be 
1.093 g/cm
3
 and 1.110g/cm
3
, respectively.
15
 
    The configuration of the MagLev device that we used is  shown in 
Figure 2. When an object is placed in the container within the 
MagLev device, the “levitation height” is defined as the distance 
from the center of the object to the bottom magnet (aligned along the 
perpendicular distance between two magnets). With this setup, a 
low-density object will levitate at a higher height compared to a 
denser object. We separated the enantiomer and racemic crystals of 
ibuprofen by levitating in aqueous 0.55M MnCl2 and tilting the 
MagLev device at 30° for optimum resolution (see Supporting 
Information for details). 
     
Figure 3. Particle size distribution of S-ibuprofen and RS-ibuprofen crystals 
measured using optical microscopy. The error bars represent standard deviation 
from seven independent measurements (n=7). 
    Particle size distribution is important when performing MagLev 
because the separation is slower as the particle size decreases (due to 
both Brownian motion and fluid shear).7 Therefore, we performed 
particle size measurements on ibuprofen crystals using an optical 
microscope. Figure 3 show that particles of S-ibuprofen (with a 
mean size of 30 µm) have smaller sizes than those of RS-ibuprofen 
(with a mean size of 48 µm). The size of these particles is very close 
to the particle size of the API commonly used in pharmaceutical 
crystallization processes. 
    To evaluate the accuracy of MagLev as an analytical tool for 
measurement of enantiomeric purity, we conducted the separation 
from prepared ibuprofen mixtures of known compositions. Taking 
run No. 6 (refer to Table 1) as an example, a prepared mixture of 
197.62 mg S- and 2.61 mg RS- ibuprofen (98.7%ee) was first 
dispersed in the glass bottle filled with paramagnetic medium 
(0.55M aqueous manganese chloride). Then the glass bottle was 
placed in the MagLev device. The Maglev device was tilted at a 30° 
in order to increase the separation.7 After allowing the mixture to 
separate overnight (~12 hours), two populations of crystals were 
clearly visible in the sample bottle, as shown in Figure 4. The top 
and the bottom populations levitated to a height of ~ 19 mm and ~ 
16 mm, respectively. Their separation distance is ~ 12 mm (distance 
between two centers of the populations). The crystals in the top 
population were carefully removed using a 20 mL syringe attached 
to a needle while crystals in the bottom population were collected 
directly by vacuum filtration. After drying, the mass of the top and 
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bottom populations were measured. The crystals in the top 
population weighed 197.51 mg, while the bottom population had 
2.33 mg of the crystals. Compared to the total initial mass of 200.23 
mg, there was a loss of 0.39 mg   during the process (which is 
probably due to crystals sticking to the glassware or filter paper). 
During density-separation in MagLev, lower-density objects levitate 
at higher heights compared to denser objects, thus the top population 
of crystals should be S-ibuprofen (1.093 g/cm3) and the bottom 
population of crystals should be RS-ibuprofen (1.110 g/cm3). We 
performed differential scanning calorimetry (DSC) analysis on the 
crystals to confirm their compositions. Since S-ibuprofen and RS-
ibuprofen have different melting points, the melting peak area was 
used to quantify composition (see Supporting Information for 
details). 
 
Figure 4. Separation of a solid mixture of 98.7% S-ibuprofen and 1.3% RS-
ibuprofen in the MagLev device (tilted at 30°): Two populations of solid crystals 
were obtained, S-ibuprofen in the upper portion (red dotted arrow) and RS-
ibuprofen in the bottom portion (yellow arrow). (An enlarged version of the whole 
photograph is included in supporting information). 
Table 1. Enantiomeric purity of S-ibuprofen before and after density-separation 
from a mixture containing the racemate using MagLev. 
Run 
No. 
Mixture (before 
separation) (% ee) 
S-ibuprofen 
(% ee) 
RS-ibuprofen 
(% ee) 
1 48.5 95.2 5.18 
2 50.3 95.4 4.17 
3 51.0 94.9 4.26 
4 79.9 98.0 3.60 
5 91.6 98.9 2.95 
6 98.7 99.8 2.57 
 
Both populations of crystals were not 100% pure. In Run 6, the 
top population (197.51 mg) of crystals showed S-ibuprofen with 
99.8%ee purity, indicating that 0.2 %wt of the crystals were RS-
ibuprofen (Table 1). Crystals found at the bottom population (2.33 
mg) exhibited 2.57%ee purity, indicating 2.57%wt of the crystals 
were S-ibuprofen. Table 1 summarizes the results of six different 
separations from different initial mixtures. The contaminations in 
both populations were present in all six separations (and will be dis-
cussed in a later section). From Table 1, we see that the 
reproducibility and selectivity of the separations are good. Run 1-3, 
starting at similar compositions (~ 50%ee), showed similar 
separation results: ~ 95%ee in the top population with a standard 
deviation of ±0.2%. In addition, Run 6 with an initial purity of 
98.7%ee could be separated into two distinguishable populations. 
Table 2. Comparison of enantiomeric purity analyzed using MagLev to the 
actual values calculated from the composition of the prepared mixture. 
Run 
No. 
Esimated value by 
MagLev (% ee) 
Actual value  
(% ee) 
Error(% ee) 
1 48.1 48.5 -0.4 
2 50.6 50.3 +0.3 
3 51.5 51.0 +0.5 
4 80.5 79.9 +0.6 
5 92.3 91.6 +0.7 
6 98.8 98.7 +0.1 
 
We determined enantiomeric purity using integrated melting peak 
areas from DSC analysis (See Supporting Information for details). 
For convenience, we define racemic crystals in a bulk of enantiopure 
crystals or enantiopure crystals in a bulk of racemic crystals as 
“impurity” crystals. The analysis showed enantioenrichment 
although traces of the “impurity” crystals exist in each population. 
This is probably due to the fact that the “impurity” crystals in both 
populations are present in small amounts (< ~5%wt), and thus do not 
show significant effect on the analysis. Table 2 summarizes the 
results of enantiomeric purity analysis using MagLev. Taking run 6 
as an example, the top and bottom populations weighed 197.51 mg 
and 2.33 mg.  Assuming that 197.51 mg are all S-ibuprofen crystals 
and 2.33 mg are all RS-ibuprofen, the enantiomeric purity of the 
initial mixture is calculated to be 98.8%ee (estimated value by 
MagLev). The mixture was prepared with 197.62 mg S-ibuprofen 
and 2.61 mg RS-ibuprofen (so the actual value is 98.7%ee). 
Therefore, the estimated value by MagLev showed a +0.1% 
difference.  All the other 5 runs also showed errors < 1.0%. These 
results suggest that MagLev can be used as a simple and efficient 
method for analysis of enantiomeric purity and enantioenrichment 
from a mixture containing the enantiomer and racemate. 
Table 3. Enantiomeric purity of S-ibuprofen (top population) after four sequential 
density-separations using MagLev. 
Number of 
Separations 
1 2 3 4 
Purity of top 
population 
95.1%ee 97.2%ee 98.6%ee 99.2%ee 
 
Beginning with an initial mixture having enantiomeric purity of 
~50%ee, we obtained ~ 5%wt of the racemic compound “impurity” 
crystals in the top population after separation in Maglev (run 1 in 
Table 1). This result inspired our interest to perform iterative 
purification steps to increase %ee. We removed the top population of 
crystals and dispersed them in a fresh paramagnetic solution with the 
aid of sonication and ran through another density-separation in 
MagLev (with the same operating procedure, 2nd separation). The 
purity of the top population increased from 95.1%ee to 97.2%ee 
after the 2nd separation. Then we carried out the same separation 
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procedure again on the top population (3rd separation). By repeating 
the separation procedure for a total of four times, we obtained 
99.2%ee purity in the top population. We include a figure in the 
supporting information illustrating the procedure for iterative 
separations of the top population and table 3 summarizes the 
enantiomeric purity of the top population after each separation step. 
As the number of separations increased, the enantiomeric purity of 
the top population increased. After four sequential separations, an 
initial mixture of ~ 50%ee was purified to a 99.2%ee product. The 
yield (defined as the percentage of final product mass over the initial 
S-ibuprofen mass) was 99.5%. These results indicate that the 
“impurity” crystals can be gradually removed from a population of 
crystals by multiple-stage separations using MagLev. The 
improvement in separation with the use of ultrasonication between 
successive separations indicates that some type of agglomeration or 
physical trapping of “impurity” crystals occurs. In addition, it 
appears that small particles play an important role in the “impurity” 
particles since (1) good separation was observed during separation of 
two millimeter sized crystals; (2) crystals smaller than 2 μm are 
strongly affected by Brownian motion and thus difficult to  separate 
into a cluster by MagLev. 
 
Conclusions 
    We have demonstrated that MagLev can be used as a simple and 
efficient method for analyzing enantiomeric purity and chiral 
separation in pharmaceutical industry. We summarize some 
highlights  here as follows: (1) Typically, separating a racemic 
compound and its corresponding enantiomers requires significant 
work to develop a HPLC method or understand complex phase 
diagrams regarding different solvents and temperatures.  In using 
MagLev method, none of the above is a concern. A small density 
difference (0.01~0.02 g/cm3) that almost exists in every chiral 
system is good enough for separation. (2) This method can be used 
for continuous separation as well. Winkleman et al. used a 
microfluidic device combined with magnets to continuously separate 
and collect polystyrene particles of different densities in a flowing 
stream of aqueous GdCl3 solution.
16,17 Although the diameters of 
these polystyrene particles (75 ~ 150 μm) are larger than the crystals 
used here, our experiments here showed that ~ 80% of particles 
(volumetric percentage by visual inspection) reached their 
equilibrium positions within 5 minutes while it takes ~12h for the 
other ~20% of particles to separate. We therefore believe that it is 
reasonable to achieve a high degree of separation in a continuous 
system as long as some considerations are taken into the process 
design regarding particle size and separation time. (3) It works well 
with small quantities which can be hard for differential 
crystallization method. In pharmaceutical drug discovery phase, 
thousands of new compounds are produced with only a few 
milligrams for screening. With MagLev, highly pure enantiomer 
compounds can be easily obtained for further tests. (4) Because the 
amount of separated racemic and enantiopure crystals are visible, 
MagLev provides an instrument-free method of detecting small 
quantities of racemic crystals (or any other impurities of different 
density) in a bulk of enantiopure crystals. (5) This method provides 
both highly pure racemic and enantiopure crystals for future use. (6) 
It gives a high degree of separation in a single step (from ~50%ee to 
~95%ee). 
In summary, the use of MagLev provides a method that is low-
cost, portable, non-destructive, and does not require electricity or 
extensive skill to operate. The analysis of enantiomeric purity was 
applied to mixtures of up to 98.7%ee, and the difference between the 
estimated values from MagLev and the actual values are all < 1.0%. 
By applying four sequential separations using MagLev, we obtained 
a highly pure S-ibuprofen product in 99.2%ee starting from a ~ 
50%ee mixture with the racemate. In addition, this method 
developed for chiral analysis and separation is not limited to the 
pharmaceutical industry, but may also be used as a general tool for 
analysis and purification in any chiral system that crystallizes into 
forms that differentiate between chiral and racemic products. The 
impurities are not limited to racemic compound crystals but can 
apply to any compounds with different densities than that of the pure 
enantiomer. We believe developing a continuous separation system 
using MagLev has potential applications in purifying enantiomers 
from products of asymmetric synthesis reactions in the production of 
chiral drugs. It could be an alternative method to solution-based 
separations (e.g., HPLC or formation of diastereomers), especially in 
resource-limited settings where these methods are inaccessible or 
expensive to develop. 
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